$39.7 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$223.25 - $468.55The lowest and highst price in the last 52 weeks.
20.69xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$39.7 Billion|
|Enterprise Value||$43.9 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||+0.5%|
|Outstanding Shares||147 Million|
|Avg 30 Day Volume||984 Thousand|
|Earnings per Share||$12.50|
|Price to Sales Ratio||3.47|
|Price to Book Ratio||3.56|
|Revenue to Enterprise Value||3.96|
|EBIT to Enterprise Value||24.78|
|Total Debt to Enterprise Value||0.17|
|Debt to Equity||0.68|
|Gross Profit||$9.16 Billion|
|Net Income||$1.55 Billion|
|Quarterly Earnings Growth (YoY)||-53.1%|
|Return on Equity||14.38%|
|Return on Assets||6.32%|
|Return on Invested Capital||8.39%|
898 shares bought (1 transactions)
11,119 shares sold (3 transactions)
CEO: Josephine Price
Industry: Biological Product (except Diagnostic) Manufacturing
At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world's first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer's disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.
Biogen (NASDAQ:BIIB) had its price target decreased by Canaccord Genuity from $423.00 to $390.00 in a research note issued to investors on Friday, The Fly reports. Canaccord Genuity currently has a...Dakota Financial News, 2 days ago
Biogen Inc. (NASDAQ:BIIB) Investment analysts at Jefferies Financial Group increased their Q1 2022 earnings per share (EPS) estimates for Biogen in a research note issued on Wednesday, October 20t...Dakota Financial News, 3 days ago
Biogen Inc. (NASDAQ:BIIB) Equities research analysts at Jefferies Financial Group raised their FY2021 earnings estimates for shares of Biogen in a research report issued on Wednesday, October 20th...Dakota Financial News, 4 days ago